<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158030">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01851993</url>
  </required_header>
  <id_info>
    <org_study_id>A02-M16-13B Ondansetron</org_study_id>
    <nct_id>NCT01851993</nct_id>
  </id_info>
  <brief_title>Inhaled Ondansetron &amp; Dyspnea</brief_title>
  <official_title>Effects of Inhaled Ondansetron on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Dyspnea&quot; refers to the awareness of breathing discomfort that is typically experienced
      during exercise in health and disease.  In various participant populations, dyspnea is a
      predictor of disability and death; and contributes to exercise intolerance and an adverse
      health-related quality-of-life.  It follows that alleviating dyspnea and improving exercise
      tolerance are among the principal goals of disease management.  Nevertheless, the effective
      management of dyspnea and activity-limitation remains an elusive goal for many healthcare
      providers and current strategies aimed at reversing the underlying chronic disease are only
      partially successful in this regard.  Thus, research aimed at identifying dyspnea-specific
      medications to complement existing therapies for the management of exertional symptoms is
      timely and clinically relevant.  The purpose of this study is to test the hypothesis that
      single-dose inhalation of nebulized ondansetron (a serotonin 5-HT3 receptor antagonist) will
      improve the perception of dyspnea during strenuous exercise in health, young men in the
      presence of an external thoracic restriction.  To this end, the investigators will compare
      the effects of inhaled 0.9% saline placebo and inhaled ondansetron (8 mg) on detailed
      assessments of neural respiratory drive, ventilation, breathing pattern, dynamic operating
      lung volumes, contractile respiratory muscle function, cardio-metabolic function and dyspnea
      (sensory intensity and affective responses) during symptom-limited, high-intensity,
      constant-work-rate cycle exercise testing with and without external thoracic restriction in
      28 healthy, men aged 20-40 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sensory Intensity (Borg 0-10 scale) ratings of dyspnea at isotime</measure>
    <time_frame>Participants will be followed until all study visits are complete, an expected average of 3 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>CWS+Ondansetron (8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chest wall strapping to reduce vital capacity by 20% of it's baseline value + single-dose inhalation of nebulized ondansetron (8 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CWS+0.9% saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Chest wall strapping to reduce vital capacity by 20% of it's baseline value + single-dose inhalation of 0.9% saline placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No CWS+Ondansetron (8 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No chest wall strapping (unloaded control) + single-dose inhalation of nebulized ondansetron (8 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No CWS+0.9% saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <arm_group_label>CWS+Ondansetron (8 mg)</arm_group_label>
    <arm_group_label>No CWS+Ondansetron (8 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CWS</intervention_name>
    <description>Chest wall strapping to reduce vital capacity by 20% of it's baseline value</description>
    <arm_group_label>CWS+Ondansetron (8 mg)</arm_group_label>
    <arm_group_label>CWS+0.9% saline placebo</arm_group_label>
    <other_name>CWS: chest wall strapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline</description>
    <arm_group_label>CWS+0.9% saline placebo</arm_group_label>
    <arm_group_label>No CWS+0.9% saline placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Aged 20-40 years

          -  FEV1 â‰¥80% predicted

          -  FEV1/FVC &gt;70%

        Exclusion Criteria:

          -  Current or ex-smoker

          -  Body Mass Index &lt;18.5 or &gt;30 kg/m2

          -  History of cardiovascular, vascular, respiratory, renal, liver, musculoskeletal,
             endocrine, neuromuscular and/or metabolic disease/dysfunction.

          -  Taking doctor prescribed medications

          -  Allergy to latex

          -  Allergy to lidocaine or its &quot;caine&quot; derivatives
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Jensen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennis Jensen, Ph.D.</last_name>
    <phone>514-398-4184</phone>
    <phone_ext>0572</phone_ext>
    <email>dennis.jensen@mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Exercise &amp; Respiratory Physiology Laboratory (CERPL) of McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W1S4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Jensen, Ph.D.</last_name>
      <phone>514-398-4184</phone>
      <phone_ext>0572</phone_ext>
      <email>dennis.jensen@mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.mcgill.ca/cerpl</url>
    <description>Clinical Exercise &amp; Respiratory Physiology Laboratory (CERPL) of McGill University</description>
  </link>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 31, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Dennis Jensen, Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Ondansetron</keyword>
  <keyword>Exercise</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
